Scientists Pinpoint Senescent Stem Cells Driving Osteoarthritis in Subchondral Bone
A multiomic study identifies EGFR⁺ stem cells and EREG⁺ macrophages as a senescent unit fueling joint degeneration — and a druggable target.
Summary
Researchers used single-cell RNA sequencing and spatial transcriptomics to map cellular senescence in osteoarthritic joint tissues from humans and mice. They discovered that EGFR⁺ mesenchyme-derived stem/progenitor cells (MDSPCs) in subchondral bone become senescent during OA, driven by the signaling molecule EREG secreted by neighboring EREG⁺ macrophages. This paracrine interaction forms a 'senescent skeletal unit' that promotes excessive bone hardening and pain. Blocking EREG — via AAV-mediated knockdown or genetic knockout in mice — reduced stem cell senescence, subchondral bone sclerosis, and OA-related pain. The findings position EREG and EGFR⁺ MDSPCs as promising therapeutic targets for osteoarthritis.
Detailed Summary
Osteoarthritis (OA) affects hundreds of millions globally, yet no disease-modifying treatments exist beyond pain management and eventual joint replacement. While cartilage degradation has historically been the focus of OA research, growing evidence suggests subchondral bone pathology may actually precede and drive cartilage loss. This study set out to characterize the role of cellular senescence in stem cell populations residing in subchondral bone during OA progression.
Using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) on osteochondral tissue from human OA patients and a murine post-traumatic OA (PTOA) model, researchers mapped the full landscape of cell types present in articular subchondral bone. Analysis revealed that mesenchyme-derived stem/progenitor cells (MDSPCs) expressing EGFR were significantly enriched in OA subchondral bone, displayed hallmarks of cellular senescence (elevated p16, p21, SA-β-gal activity, and senescence-associated secretory phenotype factors), and were spatially co-localized with EREG⁺ macrophages in histological sections.
Cell-cell communication analyses identified EREG — a member of the epidermal growth factor family — secreted by macrophages as the key paracrine signal activating EGFR on MDSPCs and inducing their senescence. In vitro experiments confirmed that EREG treatment drove EGFR⁺ MDSPCs into senescence and promoted excessive osteogenic differentiation, consistent with the subchondral bone sclerosis seen in OA. This EREG⁺ macrophage / EGFR⁺ MDSPC pairing was termed a 'senescent skeletal unit.'
In vivo, both AAV-mediated knockdown of Ereg and Ereg genetic knockout in mice subjected to destabilization of the medial meniscus (DMM) surgery significantly reduced EGFR⁺ MDSPC senescence in subchondral bone, attenuated pathological bone sclerosis, preserved articular cartilage integrity, and reduced pain-related behaviors. These functional rescue experiments validated EREG as a causal driver — not merely a marker — of OA-associated subchondral pathology.
This work establishes stem cell senescence in subchondral bone as a central mechanistic event in OA progression and identifies a targetable niche interaction between macrophage-derived EREG and EGFR⁺ MDSPCs. The study provides a compelling rationale for developing EREG-blocking or senolytic strategies focused on subchondral bone as a new therapeutic avenue for OA.
Key Findings
- EGFR⁺ MDSPCs in subchondral bone accumulate with OA progression and exhibit robust senescence markers.
- EREG⁺ macrophages form a 'senescent skeletal unit' with EGFR⁺ MDSPCs via paracrine EREG–EGFR signaling.
- EREG drives EGFR⁺ MDSPC senescence and excessive osteogenesis in vitro, mimicking OA bone sclerosis.
- AAV-mediated Ereg knockdown and genetic Ereg KO in OA mice reduced subchondral sclerosis and pain.
- Spatial transcriptomics confirmed EREG⁺ macrophage–EGFR⁺ MDSPC co-localization specifically in OA bone.
Methodology
The study combined scRNA-seq and spatial transcriptomics on human OA osteochondral tissues and a murine DMM post-traumatic OA model. Functional validation used in vitro EREG stimulation assays, AAV5-mediated Ereg shRNA knockdown, and conditional Ereg knockout mice to assess senescence, osteogenesis, and OA severity.
Study Limitations
The study relies on a surgically induced murine OA model (DMM) which may not fully replicate slow-onset human OA. Human tissue analyses are cross-sectional and cannot establish temporal causality. Translation of AAV-based Ereg knockdown to clinical use faces significant delivery and safety challenges.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.